Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021

移植片対宿主病(GVHD)治療薬の世界市場2017-2021

◆タイトル:Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021
◆商品コード:IRTNTR14217
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年8月16日
◆ページ数:78
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

TechNavioが出版した当調査レポートでは、移植片対宿主病(GVHD)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、疾患概要、移植片対宿主病(GVHD)治療薬の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は移植片対宿主病(GVHD)治療薬の世界市場が2017-2021年期間中に年平均7.15%成長すると予測しています。当レポート上に記載されている主な企業は• Bristol-Myers Squibb• Novartis• Pfizer• F. Hoffmann-La Roche等です。

About Graft vs Host Disease (GVHD) Treatment
Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient’s adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor’s organ/cell are used for transplantation compared with autologous transplant, a transplant where individual’s cells have been used for transplant.

Technavio’s analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bristol-Myers Squibb
• Novartis
• Pfizer
• F. Hoffmann-La Roche

[Other prominent vendors]
• Abbott
• AbbVie
• Allergan
• Anterogen
• Astellas Pharma
• Athersys
• Baxter
• Caladrius
• Cellular Biomedicine Group
• Cipla
• Eisai
• Eli Lilly
• GlaxoSmithKline
• Glenmark
• Helsinn Healthcare
• Heron Therapeutics
• Incyte Corporation
• IPCA Laboratories
• Kadmon Holdings
• Lupin
• Osiris Therapeutics
• RedHill
• Sanofi
• Shire
• Sun Pharmaceutical Industries
• Takeda Pharmaceutical
• ViaCyte

[Market driver]
• Increased prevalence of cancer
• For a full, detailed list, view our report

[Market challenge]
• Off-label use of drugs
• For a full, detailed list, view our report

[Market trend]
• Inorganic growth strategies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Market overview
• Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by disease type
• Acute GVHD

PART 09: Geographical segmentation
• GVHD treatment market in Americas
• GVHD treatment market in EMEA
• GVHD treatment market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Inorganic growth strategies
• Newer applications of bone marrow transplant
• Growing focus toward the use of biologics

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Novartis
• Pfizer
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Mechanism of GVHD
Exhibit 02: Global GVHD treatment market growth promoters
Exhibit 03: Major acute GVHD symptoms
Exhibit 04: Major chronic GVHD symptoms
Exhibit 05: Global GVHD treatment market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global GVHD treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline molecules as per vendors
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global GVHD treatment market by disease type 2016
Exhibit 11: Symptoms in acute GVHD
Exhibit 12: Global acute GVHD treatment market 2016-2021 ($ millions)
Exhibit 13: Symptoms in chronic GVHD
Exhibit 14: Global chronic GVHD treatment market 2016-2021 ($ millions)
Exhibit 15: Segmentation of global GVHD treatment market by geography 2016 and 2021
Exhibit 16: Segmentation of global GVHD treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Market scenario in Americas
Exhibit 18: GVHD treatment market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: GVHD treatment market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: GVHD treatment market in APAC 2016-2021 ($ millions)
Exhibit 23: Percentage distribution of transplants by organ in US (1988-2016)
Exhibit 24: Various major types of cancers managed by bone marrow transplant
Exhibit 25: Various off-label drugs used in the management of GVHD
Exhibit 26: Various symptoms and disorders associated with GVHD
Exhibit 27: Legal and ethical issues in countries
Exhibit 28: Inorganic growth strategies
Exhibit 29: Newer applications of bone marrow transplant
Exhibit 30: Competitive structure analysis of global GVHD treatment market 2016
Exhibit 31: Market penetration of various GVHD drugs manufacturers worldwide 2016
Exhibit 32: Strategic success factors of companies in global GVHD treatment market
Exhibit 33: Bristol-Myers Squibb: Key highlights
Exhibit 34: Bristol-Myers Squibb: Strength assessment
Exhibit 35: Bristol-Myers Squibb: Strategy assessment
Exhibit 36: Bristol-Myers Squibb: Opportunity assessment
Exhibit 37: F. Hoffmann-La Roche: Key highlights
Exhibit 38: F. Hoffmann-La Roche: Strength assessment
Exhibit 39: F. Hoffmann-La Roche: Strategy assessment
Exhibit 40: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 41: Novartis: Key highlights
Exhibit 42: Novartis: Strength assessment
Exhibit 43: Novartis: Strategy assessment
Exhibit 44: Novartis: Opportunity assessment
Exhibit 45: Pfizer: Key highlights
Exhibit 46: Pfizer: Strength assessment
Exhibit 47: Pfizer: Strategy assessment
Exhibit 48: Pfizer: Opportunity assessment



【掲載企業】

Bristol-Myers Squibb, Novartis, Pfizer, F. Hoffmann-La Roche, bbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Baxter, Caladrius, Cellular Biomedicine Group, Cipla, Eisai, Eli Lilly, GlaxoSmithKline, Glenmark, Helsinn Healthcare, Heron Therapeutics, Incyte Corporation, IPCA Laboratories, Kadmon Holdings, Lupin, Osiris Therapeutics, RedHill, Sanofi, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and ViaCyte.


★調査レポート[移植片対宿主病(GVHD)治療薬の世界市場2017-2021] (Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021 / IRTNTR14217)販売に関する免責事項
[移植片対宿主病(GVHD)治療薬の世界市場2017-2021] (Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021 / IRTNTR14217)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆